These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32653650)

  • 1. The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2.
    Ma Q; Qiu M; Zhou H; Chen J; Yang X; Deng Z; Chen L; Zhou J; Liao Y; Chen Q; Zheng Q; Cai L; Shen L; Yang Z
    Pharmacol Res; 2020 Oct; 160():105073. PubMed ID: 32653650
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo.
    Deng W; Xu Y; Kong Q; Xue J; Yu P; Liu J; Lv Q; Li F; Wei Q; Bao L
    Signal Transduct Target Ther; 2020 May; 5(1):66. PubMed ID: 32385228
    [No Abstract]   [Full Text] [Related]  

  • 3. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).
    Huang F; Li Y; Leung EL; Liu X; Liu K; Wang Q; Lan Y; Li X; Yu H; Cui L; Luo H; Luo L
    Pharmacol Res; 2020 Aug; 158():104929. PubMed ID: 32442720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.
    Lisi L; Lacal PM; Barbaccia ML; Graziani G
    Biochem Pharmacol; 2020 Oct; 180():114169. PubMed ID: 32710969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
    Nisole S; Saulnier A; Gatignol A
    Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
    [No Abstract]   [Full Text] [Related]  

  • 6. The pros and cons of traditional Chinese medicines in the treatment of COVID-19.
    Wang Y; Zeng X; Zhao Y; Chen W; Chen YZ
    Pharmacol Res; 2020 Jul; 157():104873. PubMed ID: 32371086
    [No Abstract]   [Full Text] [Related]  

  • 7. Xuebijing injection in the treatment of COVID-19: a retrospective case-control study.
    Guo H; Zheng J; Huang G; Xiang Y; Lang C; Li B; Huang D; Sun Q; Luo Y; Zhang Y; Huang L; Fang W; Zheng Y; Wan S
    Ann Palliat Med; 2020 Sep; 9(5):3235-3248. PubMed ID: 32954754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies?
    Magro G
    Travel Med Infect Dis; 2020; 37():101685. PubMed ID: 32334088
    [No Abstract]   [Full Text] [Related]  

  • 9. Purposing Saikosaponins for the treatment of COVID-19.
    Bahbah EI; Negida A; Nabet MS
    Med Hypotheses; 2020 Jul; 140():109782. PubMed ID: 32353743
    [No Abstract]   [Full Text] [Related]  

  • 10. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
    Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
    Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.
    Li C; Wang L; Ren L
    Virus Res; 2020 Sep; 286():198073. PubMed ID: 32592817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythema multiforme in the context of SARS-Coronavirus-2 infection.
    Sánchez-Velázquez A; Falkenhain D; Rivera Díaz R
    Med Clin (Barc); 2020 Aug; 155(3):141. PubMed ID: 32475615
    [No Abstract]   [Full Text] [Related]  

  • 13. Rapid repurposing of drugs for COVID-19.
    Guy RK; DiPaola RS; Romanelli F; Dutch RE
    Science; 2020 May; 368(6493):829-830. PubMed ID: 32385101
    [No Abstract]   [Full Text] [Related]  

  • 14. Network pharmacology suggests biochemical rationale for treating COVID-19 symptoms with a Traditional Chinese Medicine.
    Zhang DH; Zhang X; Peng B; Deng SQ; Wang YF; Yang L; Zhang KZ; Ling CQ; Wu KL
    Commun Biol; 2020 Aug; 3(1):466. PubMed ID: 32811894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology.
    Dal Moro F; Livi U
    Clin Immunol; 2020 May; 214():108414. PubMed ID: 32272196
    [No Abstract]   [Full Text] [Related]  

  • 16. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
    Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
    In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The database-based strategy may overstate the potential effects of traditional Chinese medicine against COVID-19.
    Huang YX; Wang WX; Zhang S; Tang YP; Yue SJ
    Pharmacol Res; 2020 Sep; 159():105046. PubMed ID: 32590099
    [No Abstract]   [Full Text] [Related]  

  • 18. News Feature: To counter the pandemic, clinicians bank on repurposed drugs.
    Madhusoodanan J
    Proc Natl Acad Sci U S A; 2020 May; 117(20):10616-10620. PubMed ID: 32350142
    [No Abstract]   [Full Text] [Related]  

  • 19. Investigating hypothiocyanite against SARS-CoV-2.
    Cegolon L
    Int J Hyg Environ Health; 2020 Jun; 227():113520. PubMed ID: 32305009
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-COVID drugs: repurposing existing drugs or search for new complex entities, strategies and perspectives.
    Pawełczyk A; Zaprutko L
    Future Med Chem; 2020 Oct; 12(19):1743-1757. PubMed ID: 32698626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.